The FDA’s TRT Panel Validated What Hone’s Data Already Shows

by Saad Alam, CEO Hone Health

An FDA panel on Dec. 10 recommended fundamental changes to how testosterone is regulated and prescribed that could prevent thousands of premature deaths from cardiovascular disease, diabetes, and metabolic dysfunction. The panel’s conclusions validate what Hone Health’s patient data has shown for years: testosterone decline isn’t simply a normal part of aging; it’s an early warning system that traditional healthcare has been ignoring.

Low testosterone isn’t just a sex hormone issue or a vanity metric. It’s correlated with metabolic syndrome, type 2 diabetes and cardiovascular disease. Men with low T are 52% more likely to have diabetes, 69% more likely to have obesity, and twice as likely to die prematurely. Often, it’s the canary in the metabolic coal mine—one of the earliest measurable signals that a man is at risk for one of these chronic diseases that shorten your healthspan.

Hone patients often present with borderline insulin resistance, slightly elevated inflammatory markers, and declining testosterone months or even years before they meet the diagnostic criteria for diabetes or develop clinically significant cardiovascular disease. Often, they have few symptoms that would otherwise raise red flags. 

One of the experts on the panel suggested that all men over 40 should be screened for low testosterone to get a baseline that can be tracked over time. That’s a good starting point, but here’s the problem: Traditional medicine checks testosterone as a standalone marker. A single total testosterone level, viewed in isolation, tells you very little about what’s actually happening in a man’s body.

Testosterone needs to be analyzed within a comprehensive metabolic picture—sex hormones, metabolic markers, lipids, inflammation, body composition—that allow us to identify patterns that predict diseases before they manifest.

Recently, a 42-year-old patient came to us with fatigue and weight gain. His PCP had checked his testosterone once—it was 380 ng/dL, technically “normal.” But when we looked at his complete panel, we saw declining free testosterone, rising inflammatory markers, early insulin resistance, and shifting lipid ratios.

We treated him—not just with testosterone replacement therapy, but with metabolic support, lifestyle modifications, and ongoing monitoring. Six months later, his markers had stabilized. More importantly, we reversed a trajectory that was heading toward diabetes and cardiovascular disease.

Barriers to Access

The panel also addressed significant barriers preventing men from accessing appropriate care. Testosterone’s Schedule III classification—a designation stemming from 1990s athletic doping concerns—creates unnecessary obstacles.

Every day we hear from men whose PCPs were reluctant to prescribe TRT, or whose pharmacists treated their filling a legitimate prescription with suspicion. Men feel stigmatized for seeking treatment for a measurable medical condition.

There’s no scientific basis for this classification of hormone optimization at therapeutic doses. Descheduling would align testosterone with how we treat other exogenous hormones like estrogen and progesterone, which are all tightly regulated without controlled substance designation.

But the access problem extends beyond scheduling. The FDA’s current labeling restricts testosterone therapy to men with “classical hypogonadism,” rare disorders of the testicles or pituitary gland. This framework doesn’t reflect the population in which testosterone deficiency actually appears: men with age-related metabolic factors including weight gain, insulin resistance, chronic disease, and stress.

The gap between clinical guidelines and FDA labeling leaves men in limbo. If symptoms and labs point clearly to testosterone deficiency, but the cause doesn’t fit the narrow FDA definition, patients face coverage denials and clinician hesitation—even though treatment is standard of care.

What Needs to Happen

The healthcare system needs to move from reactive sick care—treating disease after it appears—to proactive monitoring that identifies risk trajectories before they become irreversible conditions.

This means testing and tracking testosterone alongside other markers to help health care professionals to identify patterns early and intervene appropriately—whether through hormone optimization, metabolic support, lifestyle modification, or all of the above.

The traditional model treats testosterone as a yes/no question: Is it low enough to treat? The better model considers it part of a longevity story: What is this biomarker telling us about this patient’s overall trajectory, and which interventions will change that trajectory most effectively?

This is the system Hone has built. It’s the system the FDA panel implicitly endorsed. And it’s the system American men deserve access to.

The science is clear. The data is consistent. The expert consensus has shifted. What remains is the willingness to update policy to match reality.

Testosterone is not a performance drug. It’s not a lifestyle enhancement. It’s a core health indicator that, when understood properly and monitored comprehensively, gives us the ability to identify and prevent some of the most common causes of male morbidity and mortality.

The FDA panel validated this understanding. Now the healthcare system needs to act on it.

Interested in reading more about testosterone?

Learn More

About the author

Saad Alam is the CEO and co-founder of Hone, a modern health optimization platform that helps men and women take charge of their hormones, metabolism, and longevity through advanced biomarker testing and personalized, clinician-guided care.